umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease
Umeå universitet, Medicinska fakulteten, Institutionen för samhällsmedicin och rehabilitering, Geriatrik.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi, Virologi.
Umeå universitet, Medicinska fakulteten, Institutionen för odontologi. Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Näringsforskning. (Aa-gruppen)ORCID-id: 0000-0002-8069-8263
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Alzheimer's & Dementia, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 13, nr 7, s. 778-782Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Introduction: Biomarkers that identify individuals at risk of Alzheimer's disease (AD) development would be highly valuable. Plasma concentration of amyloid β (Aβ)—central in the pathogenesis of AD—is a logical candidate, but studies to date have produced conflicting results on its utility.

Methods: Plasma samples from 339 preclinical AD cases (76.4% women, mean age 61.3 years) and 339 age- and sex-matched dementia-free controls, taken an average of 9.4 years before AD diagnosis, were analyzed using Luminex xMAP technology and INNO-BIA plasma Aβ form assays to determine concentrations of free plasma Aβ40 and Aβ42.

Results: Plasma concentrations of free Aβ40 and Aβ42 did not differ between preclinical AD cases and dementia-free controls, in the full sample or in subgroups defined according to sex and age group (<60 and ≥ 60 years). The interval between sampling and AD diagnosis did not affect the results. Aβ concentrations did not change in the years preceding AD diagnosis among individuals for whom longitudinal samples were available.

Discussion: Plasma concentrations of free Aβ could not predict the development of clinical AD, and Aβ concentrations did not change in the years preceding AD diagnosis in this sample. These results indicate that free plasma Aβ is not a useful biomarker for the identification of individuals at risk of developing clinical AD.

Ort, förlag, år, upplaga, sidor
Elsevier, 2017. Vol. 13, nr 7, s. 778-782
Nyckelord [en]
Plasma amyloid β, Aβ, Alzheimer's disease, Dementia, Preclinical Alzheimer's disease, Biomarker
Nationell ämneskategori
Neurologi
Forskningsämne
geriatrik
Identifikatorer
URN: urn:nbn:se:umu:diva-126471DOI: 10.1016/j.jalz.2016.12.004ISI: 000404559300006OAI: oai:DiVA.org:umu-126471DiVA, id: diva2:1033504
Tillgänglig från: 2016-10-07 Skapad: 2016-10-07 Senast uppdaterad: 2018-08-31Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltext

Personposter BETA

Lövheim, HugoElgh, FredrikJohansson, AndersHallmans, GöranEriksson, Sture

Sök vidare i DiVA

Av författaren/redaktören
Lövheim, HugoElgh, FredrikJohansson, AndersHallmans, GöranEriksson, Sture
Av organisationen
GeriatrikVirologiInstitutionen för odontologiNäringsforskningEnheten för biobanksforskning
I samma tidskrift
Alzheimer's & Dementia
Neurologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 471 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf